Why this matters more than ever in 2026
Three forces reshaped the compounded GLP-1 telehealth market between January and April 2026, and they directly affect which provider you should choose:
- FDA enforcement wave (March 2026). The agency sent warning letters to approximately 30 telehealth companies regarding promotional claims about compounded GLP-1 products. The warnings concentrated on marketing language, not the active ingredients themselves. Several smaller operators shut down; larger players (including SkinnyRx) received warnings but continued operating after revising their language.
- Wegovy oral pill launch (January 5, 2026). Novo Nordisk launched the FDA-approved oral semaglutide tablet for chronic weight management, starting at $149/month for lower doses and reaching $299/month for the 25 mg daily dose. This created a new "branded path" option that competes directly with compounded subscriptions.
- Compounded prices dropped 30-50%. Increased competition pushed compounded semaglutide prices from a 2024 average of $300-400/month down to $115-249/month in 2026. Pomegranate Health listed $115/month as of May 2026 (per the provider) — about 90% less than brand Wegovy ($1,000-1,300/month without insurance).
The takeaway: quality variance between providers is now wider than ever. Some have FDA warnings, some have stellar records. Some have transparent pricing, some hide fees. This guide ranks them by what actually matters.
What is a 503A pharmacy? (Quick refresher)
503A pharmacies are licensed compounding pharmacies operating under the FDA Modernization Act of 1997. They legally produce custom medications for individual patients with valid prescriptions. The compounded GLP-1 medications you find through legitimate telehealth providers come from 503A pharmacies.
Key facts:
- 503A compounding is legal when done correctly — it requires a valid patient prescription and a state-licensed pharmacy.
- The active ingredient (semaglutide, tirzepatide) is chemically the same molecule as the branded version.
- However, compounded versions are NOT FDA-approved as finished products, meaning the FDA has not reviewed and approved each batch's potency, purity, and stability.
- Quality depends heavily on the pharmacy. Reputable telehealth providers disclose their pharmacy partner; sketchy ones do not.
If your provider will not name their compounding pharmacy or refuses to send a Certificate of Analysis (CoA) when asked, that's a red flag.
How we evaluated providers
Our criteria for ranking these 8 telehealth providers:
- Pricing transparency — flat monthly rate vs. hidden fees
- Pharmacy partner disclosure — do they name their 503A pharmacy?
- Provider quality — real licensed MDs/NPs with proper consultations
- FDA standing — any warning letters? How did they respond?
- Onboarding speed — time from sign-up to medication shipped
- Refund and cancellation policy — clear and customer-friendly?
- Real user reviews — Reddit, Trustpilot, BBB through May 2026
The 7 providers compared at a glance
| Provider | Type | Price/mo | FDA Status | Could Suit |
|---|---|---|---|---|
| SkinnyRx | Compounded | Check the current price on SkinnyRx's site | ⚠️ Warning letter (revised) | Compounded option |
| Hims & Hers | Branded (FDA-approved) | $299-499 | ✅ Clean | Lowest risk |
| Pomegranate Health | Compounded | $115-134 | No warnings | Cheapest legitimate |
| Coreage RX | Pharma-grade | $199 | No warnings | Pharma-grade at compounded price |
| Mochi Health | Compounded + dietitian | ~$199 | No warnings | Holistic care |
| Brello Health | Compounded + B6 | $133 | No warnings | Anti-nausea add-on |
| Get Thin MD | Compounded + 24/7 | $149 | No warnings | Service-first model |
| bmiMD NEW | Compounded Sema + Tirz | Personalized | ✅ Clean | bmiMD reports 80K+ members |
| Peter MD NEW | Men's GLP-1 + TRT + NAD+ | Check Peter MD's site for current pricing | ✅ Clean | Men's multi-vertical hormone+GLP-1 |
Prices are as listed on each provider's site in May 2026 and have not been re-verified since. Check the provider's site for current pricing before signing up.
Highlighted rows (green tint) are GLP-1 Evolution affiliate partners. Other rows are listed for fair comparison and are NOT affiliate links — meaning we receive zero compensation if you choose those providers. Pricing as of May 2026; verify directly.
Want this comparison as a PDF?
11 providers compared by real cost. Subscribe for the monthly digest, or download the PDF directly.
Educational. Affiliate links. Not medical advice. No spam. Full disclosure
SkinnyRx (with caveats)
Price: Check the current price on SkinnyRx's site for compounded semaglutide
Approval time: 24-48 hours typical
Pharmacy: Operated by Lean Rx, Inc. (Sacramento, CA)
Formulations: Injectable, sublingual, tablet
SkinnyRx offers compounded formulations in three forms: injectable, sublingual, and oral tablet versions for users who prefer not to inject.
The FDA context: SkinnyRx received a warning letter from the FDA in early 2026 regarding promotional claims that the agency considered misbranding under the Food, Drug, and Cosmetic Act. The product line continued operating; SkinnyRx revised the flagged marketing language. This is not the same as a product recall or safety enforcement — it was specifically about advertising. We mention it for transparency, not to disqualify.
Pros: Three formulation options (injectable/sublingual/tablet), fast approval, 30-day money-back guarantee (per the provider; check terms), transparent pharmacy disclosure, Affirm financing available (split your subscription into monthly payments — useful if you prefer not to pay the full amount upfront).
Cons: The FDA warning is a real consideration — if you want a provider with no past warnings, choose differently. Customer support response times can lag during high-volume periods.
👉 Visit SkinnyRx → (affiliate link — see disclosure)
Hims & Hers (FDA-approved branded option)
Price: $299-499/month for FDA-approved Wegovy or Zepbound (as listed by the provider, May 2026; verify current pricing)
Approval time: 24-72 hours
Pharmacy: Branded medications shipped from major pharmacies; no compounding uncertainty
Formulations: FDA-approved injectable (Wegovy, Zepbound)
Hims & Hers is publicly traded on the NYSE (ticker: HIMS) and operates the largest direct-to-consumer telehealth platform in the U.S. Their GLP-1 program defaults to FDA-approved branded medications (Wegovy semaglutide, Zepbound tirzepatide) when prior authorization or insurance allows. This is the highest-cost option in our list, but it eliminates the regulatory ambiguity of compounded medications entirely.
Pros: Massive infrastructure, 24/7 chat support, FDA-approved medications only, transparent pricing, easy cancellation, strong customer protection.
Cons: Significantly more expensive than compounded alternatives. Not as flexible on dose customization. Some users report long wait times during peak demand.
👉 Visit Hims → (not an affiliate link)
Pomegranate Health (Cheapest legitimate)
Price: $115-134/month bi-monthly delivery (as listed by the provider, May 2026; verify current pricing)
Approval time: 24-48 hours
The listed price (around $115/month for the lower dose as of May 2026, per the provider) may appeal to budget-conscious users. The trade-off: bare-bones customer service, no 24/7 support, and a less personalized experience than premium providers. Best for people who already understand GLP-1 and need ongoing access at the lowest price.
Coreage RX (Pharma-grade at compounded price)
Price: $199/month for pharmaceutical-grade semaglutide (as listed by the provider, May 2026; verify current pricing)
Coreage RX takes a different positioning: rather than compounded, they source from licensed pharmaceutical manufacturers in small batches at a price competitive with compounded providers. This eliminates compounding-related quality variance. If you want pharma-grade quality without paying Hims-level prices, this is worth considering.
Mochi Health (Holistic care)
Price: ~$199/month including dietitian consultations (as listed by the provider, May 2026; verify current pricing)
Mochi differentiates by adding registered dietitian consultations as part of the subscription. For first-time GLP-1 users who want hand-holding around lifestyle integration, this is a strong fit. Reddit feedback consistently praises the quality of provider interactions.
Brello Health (Anti-nausea add-on)
Price: $133/month including vitamin B6 to mitigate nausea (as listed by the provider, May 2026; verify current pricing)
Brello Health includes vitamin B6 with each shipment, marketed as a nausea reducer (B6 is a documented anti-nausea agent). Real user feedback notes occasional shipping delays — if a 1-2 day delay would affect your dose schedule, factor that in.
Get Thin MD (Service-first model)
Price: $149/month with 24/7 nurse hotline (as listed by the provider, May 2026; verify current pricing)
Get Thin MD competes on availability rather than price or features. Their 24/7 nurse hotline and rapid provider response is the differentiator. Best for users who anticipate questions outside business hours or who want frequent reassurance during initial titration weeks.
How to choose: a decision framework
Use this simple framework to match your priority to a provider:
- Priority is "FDA-approved branded medication": Consider Hims & Hers. FDA-approved branded medications eliminate compounding regulatory uncertainty.
- For readers prioritizing value with reasonable transparency: Consider SkinnyRx, noting that they had an FDA warning that they addressed.
- Priority is keeping costs low: Pomegranate Health at $115-134/month (as listed by the provider, May 2026; verify current pricing), accepting bare-bones service.
- Priority is "first-time GLP-1, want guidance": Mochi Health for the dietitian support.
- Priority is "minimize nausea": Brello Health (B6 add-on) or work with any provider on slow titration.
What to expect: side effects and timeline (with citations)
Side effects timing — based on the STEP 1 trial[1] (semaglutide 2.4 mg weekly) and the SURMOUNT-1 trial[5] (tirzepatide):
- Week 1-4: Nausea is most common (~44% on semaglutide, ~33% on tirzepatide). Other GI symptoms (diarrhea, constipation, vomiting) are dose-dependent.
- Week 5-12: Symptoms substantially subside as the body adapts. Slow dose titration reduces severity.
- Week 12+: Most users report tolerable side effects or none.
- Discontinuation rate due to GI: 4-5% in trials.
Weight loss curves on FDA-approved doses (clinical trial averages):
- Week 4: ~3% body weight reduction
- Week 12: ~7-9%
- Week 24: ~12-14%
- Week 48: ~14.9% (semaglutide STEP 1) to ~22.5% (tirzepatide SURMOUNT-1, 15 mg dose)
Long-term considerations: the STEP 1 trial extension[4] found that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of the weight they had lost over the following year. Plan for chronic treatment if you want sustained results — this is a key factor in choosing a provider you trust over the long term.
Frequently asked questions
What should you consider when choosing telehealth for compounded GLP-1 in 2026?
Options depend on priorities. If FDA-approved options are a priority, Hims & Hers (FDA-approved). For compounded options, SkinnyRx (check the current price on SkinnyRx's site, with the FDA warning caveat). For an option with listed pricing, Pomegranate Health ($115-134/mo as of May 2026, per the provider; verify current pricing).
Is compounded semaglutide safe?
Compounded semaglutide from licensed 503A pharmacies is regulated under the FDA Modernization Act of 1997. It is custom-made for individual patients based on a valid prescription. While not FDA-approved as a finished product, the active ingredient is the same molecule. Risks include possible variation in potency or sterility if the pharmacy is unlicensed. Verify the pharmacy is 503A-licensed.
Does compounded semaglutide work as well as Wegovy?
In principle, yes — both contain semaglutide as the active ingredient. The STEP 1 trial[1] showed -14.9% body weight loss on FDA-approved semaglutide 2.4 mg over 68 weeks. Compounded versions delivering the same active ingredient at the same dose are pharmacologically equivalent. The variable is the pharmacy's quality control.
What does the FDA warning to telehealth companies mean for me?
In March 2026 the FDA sent warning letters to approximately 30 telehealth companies regarding promotional claims that misbrand compounded GLP-1 medications. The warnings target marketing language, not necessarily the products themselves. As a consumer, read provider claims critically and prefer providers with clean FDA records or transparent disclosures of any past warnings.
How much does compounded semaglutide cost via telehealth in 2026?
Range in May 2026: $115/month (Pomegranate Health) to $299/month (premium services). Most reputable providers cluster between $149-249/month. Brand semaglutide (Wegovy) without insurance: $1,000-1,300/month. Compounded therefore offers 75-90% savings vs brand, with the regulatory caveats discussed.
Are there hidden fees in telehealth GLP-1?
Common hidden charges to watch for: initial consultation fees ($25-99), shipping fees ($15-30), restocking fees on cancellation, dose-escalation upcharges, and lab testing fees if requested. Reputable providers (Hims, SkinnyRx) typically include all these in transparent flat-rate pricing. Lower-cost providers sometimes add fees later.
How do I switch from one telehealth provider to another?
Most platforms allow cancellation within 30 days for full refund of unused product. Process: notify your current provider in writing, complete the new provider's intake (full medical history, current dose), wait for prescription approval (24-72 hours typically), and time the switch so you do not run out of medication. Avoid stopping abruptly — discuss tapering with your new provider.
Does insurance cover compounded semaglutide?
Almost never. Insurance plans cover FDA-approved branded medications (Wegovy, Ozempic, Zepbound) when prior authorization criteria are met. Compounded versions are typically not covered because they are not FDA-approved. Some HSA/FSA accounts allow compounded medication purchases — verify with your administrator.
How long do GLP-1 side effects last?
Per the STEP 1 trial[1]: nausea is the most common side effect (~44% in early weeks), typically peaking at week 4 and substantially subsiding by week 12. About 4-5% of trial participants discontinued due to GI side effects. Side effects often correlate with dose escalation — slower titration reduces severity.
What happens if I stop taking semaglutide?
The STEP 1 trial extension[4] found that participants who stopped semaglutide regained approximately two-thirds of the weight they had lost over the following year, and cardiometabolic improvements (blood pressure, lipids, A1C) reversed. This frames obesity as a chronic disease requiring ongoing treatment for sustained results.
Can I buy retatrutide through telehealth right now?
No — retatrutide completed its TRIUMPH Phase 3 trials (topline results announced by Lilly through July 2026, not yet peer-reviewed) and is NOT FDA-approved as of September 20, 2026 or available through any legitimate telehealth provider. Any product claiming to be "retatrutide" sold online before FDA approval is unregulated and potentially dangerous. Eli Lilly's TRIUMPH Phase 3 program is ongoing; FDA approval is anticipated in 2027-2028.[8]
Is the new Wegovy oral pill (launched January 2026) worth it?
The Wegovy oral tablet launched January 5, 2026, starting at $149/month for lower doses and reaching $299/month for the 25 mg daily dose. Trade-offs vs injection: convenience of pills vs strict instructions (empty stomach, max 4 oz water, wait 30 minutes before food, drink, or other oral medications). Inconsistent dosing routine reduces effectiveness. Best for users who tolerate strict morning routines.
Sources & clinical references
- [1] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
- [2] Wadden TA, et al. STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. DOI: 10.1001/jama.2021.1831
- [3] Rubino D, et al. STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224
- [4] Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension. Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14725
- [5] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
- [6] Aronne LJ, et al. SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. DOI: 10.1001/jama.2023.24945
- [7] Osumili B, et al. Tirzepatide vs semaglutide indirect treatment comparison. Diabetes Res Clin Pract. 2024;212:111717. DOI: 10.1016/j.diabres.2024.111717
- [8] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
- [9] Madsbad S, Holst JJ. The promise of GLP-1 RAs for obesity treatment. Expert Opin Investig Drugs. 2025. DOI: 10.1080/13543784.2025.2472408
- [10] Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy and resistance exercise. Diabetes Care. 2024. DOI: 10.2337/dci23-0100
Disclaimers
FTC Affiliate Disclosure: This article contains affiliate links to SkinnyRx, Hims & Hers. If you sign up through these links, we may receive commission at no additional cost to you. This does not affect our editorial assessment — providers are ranked by transparent criteria, and we explicitly identify which links are affiliate. Other providers in this article (Pomegranate Health, Coreage RX, Mochi Health, Brello Health, Get Thin MD) are NOT affiliate links and we receive zero compensation from them.
Medical Disclaimer: This article is for educational purposes only. Nothing here constitutes medical advice. Always consult a licensed healthcare provider before starting, changing, or stopping any medication. Compounded medications carry regulatory and quality considerations beyond those of FDA-approved products — discuss with a physician familiar with your medical history. Information current as of May 2026; verify current pricing and FDA standing directly with each provider.